Article Text

Review: antipsychotic augmentation is effective for people with obsessive-convulsive disorder who are receiving, but not responding to, serotonin reuptake inhibitor monotherapy

Statistics from

 Q Does augmentation with antipsychotics improve outcome for people with refractory obsessive-compulsive disorder who are not responding to serotonin reuptake inhibitor monotherapy?


Embedded ImageDesign:

Systematic review with meta-analysis.

Embedded ImageData sources:

PubMed and PsychINFO (1967–2005), EMBASE (1974–2000) and the Cochrane Central Register of Controlled Trials (Issue 3, 2005). Reference lists were hand searched.

Embedded ImageStudy selection and analysis:

Eligible studies were double blinded, randomised controlled trials (RCTs) that compared augmentation with antipsychotic versus placebo in adults with obsessive-compulsive disorder that had not responded to ⩾2 months serotonin reuptake inhibitor (SRI) monotherapy, and that used the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) as an outcome measure. Pooled absolute risk difference (RD) was used to analyse proportion of treatment responders and number needed to treat (NNT) was reported.

Embedded ImageOutcomes:

Response (defined as ⩾35% reduction in Y-BOCS score).


Nine RCTs met inclusion criteria (278 people). Antipsychotics tested …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.